Press Releases

Press Releases

Date Title
10/01/19 Vaxart to Present Clinical Data From its Norovirus Phase 1b Study at Three Global Healthcare Conferences in October 2019
ID Week (Washington, DC), 7th International Calicivirus Conference (Sydney, AU) and the 10th International Vaccines for Enteric Diseases (Lausanne, CH)   SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing
09/26/19 Vaxart Announces Pricing of $8 Million Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public
09/25/19 Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase 1b Study
Both norovirus vaccines induced substantial immune responses with no indication of immunological interference when administered concurrently Phase 2-ready oral norovirus vaccine targets potential $3B+ market opportunity SOUTH SAN FRANCISCO, Calif. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc.
09/04/19 Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 4, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour , M.D., president and chief executive officer of
08/08/19 Vaxart Announces Second Quarter 2019 Financial Results and Provides Corporate Update
- Phase 1b Bivalent Norovirus Study Fully Enrolled - - Research Collaboration with Janssen for Universal Flu Vaccine Underway - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are
07/09/19 Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc. , ( Vaxart ), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by
06/20/19 Vaxart to Present at ASM Microbe 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., senior scientist at Vaxart ,
05/29/19 New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a
05/09/19 Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
- $13 million raised in 1H19 - - Norovirus bivalent vaccine Phase 1b clinical study underway with results expected in 2H19 - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered
04/16/19 Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b